Stock listing

NASDAQ:HRMY Harmony Biosciences Holdings, Inc. Stock

Home listing (NASDAQ) of Harmony Biosciences Holdings, Inc.

Follow Harmony Biosciences Holdings, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:HRMY

$32.59 USD -0.52 (-1.6%)

Close on Nov 20, 2026

Past year -2.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$32.51 – $33.43 USDNov 20, 2026
Volume
582,639 sharesNov 20, 2026
Market cap
$1.91B USDAt the close on Nov 20, 2026 · price × 58.72M shares outstanding
52-week range
$25.90 – $43.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$38.51M USDMedian day 871,271 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Harmony Biosciences Holdings, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:HRMY · Home$32.59 USD-0.52 (-1.6%)582,639$32.68$33.43$32.51$33.11Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HRMY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$32.59-0.52-1.6%$32.68$33.43$32.51582,639
$33.11+0.10+0.3%$33.01$33.40$32.73565,813
$33.01+0.05+0.2%$32.96$33.13$32.46607,331
$32.96-0.80-2.4%$33.78$34.01$32.87710,506
$33.76-0.04-0.1%$33.80$34.32$33.01844,890
$33.80-0.42-1.2%$34.18$34.26$33.19936,219
$34.22+0.67+2.0%$33.35$34.38$33.26971,350
$33.55-0.23-0.7%$33.39$33.81$33.101,326,800
$33.78+0.67+2.0%$33.25$33.83$32.68792,900
$33.11+0.64+2.0%$32.70$33.38$32.27786,742
$32.47-1.945-5.7%$35.68$35.68$32.311,477,499
$34.42-2.605-7.0%$34.50$35.86$32.612,469,127
$37.02-0.89-2.3%$37.97$38.74$36.381,445,070
$37.91-0.85-2.2%$38.77$39.03$37.69993,610
$38.76+0.17+0.4%$38.58$39.10$38.39871,271
$38.59+0.09+0.2%$38.65$39.20$38.04778,846
$38.50+0.55+1.4%$37.72$38.53$37.281,002,679
$37.95+1.12+3.0%$36.90$37.98$36.62736,911
$36.83+0.70+1.9%$36.28$37.19$36.13850,295
$36.13+0.10+0.3%$36.11$37.05$35.002,313,565
$36.03-2.28-6.0%$38.50$39.64$34.112,905,502
$38.31-0.39-1.0%$38.58$38.93$38.131,062,532
$38.70+1.16+3.1%$37.99$39.23$37.49798,585
$37.54-0.41-1.1%$37.84$37.97$37.171,008,466
$37.95-0.32-0.8%$38.47$39.00$37.85892,300
$38.27+0.76+2.0%$38.04$39.00$38.00798,300
$37.51+0.48+1.3%$37.16$38.31$36.92972,200
$37.03-1.20-3.1%$37.91$38.17$35.991,419,000
$38.23-2.05-5.1%$38.34$39.89$37.011,148,400
$40.28+0.68+1.7%$39.53$40.57$39.51487,100
$39.60+0.26+0.7%$39.14$39.89$38.68865,000
$39.34-0.02-0.1%$39.27$39.86$39.10547,000
$39.36-0.56-1.4%$40.09$40.35$38.91507,300
$39.92+0.28+0.7%$39.76$40.77$39.51897,900
$39.64+0.07+0.2%$39.78$40.62$39.25916,700
$39.57+0.31+0.8%$39.58$40.46$39.081,227,700
$39.26-0.03-0.1%$39.30$39.56$38.72667,500
$39.29-0.72-1.8%$39.87$40.52$39.15786,700
$40.01-1.25-3.0%$41.29$41.54$39.54874,400
$41.26+0.10+0.2%$41.37$41.60$40.89556,900
$41.16+0.68+1.7%$40.63$41.79$40.00906,400
$40.48-1.05-2.5%$41.61$42.08$39.721,080,600
$41.53-0.57-1.4%$42.10$42.37$41.36577,900
$42.10+0.08+0.2%$41.87$42.52$41.20839,000
$42.02-0.72-1.7%$42.57$43.27$41.903,820,500
$42.74+0.53+1.3%$42.59$43.01$42.10641,400
$42.21+0.04+0.1%$42.28$43.05$42.061,599,200
$42.17+0.63+1.5%$41.64$42.19$40.941,212,500
$41.54+0.020.0%$41.93$42.25$41.481,044,200
$41.52+0.42+1.0%$41.30$41.72$40.921,123,400
$41.10-0.52-1.2%$41.26$41.72$40.93736,800
$41.62-0.45-1.1%$42.01$42.41$41.231,132,800
$42.07-0.18-0.4%$42.20$43.25$41.561,778,100
$42.25+0.39+0.9%$41.50$42.34$41.36661,500
$41.86-1.00-2.3%$42.93$43.49$41.401,100,600
$42.86+1.61+3.9%$41.31$43.02$41.251,167,300
$41.25+1.87+4.7%$39.38$41.49$39.38894,500
$39.38+0.17+0.4%$38.97$39.75$38.97560,200
$39.21-0.66-1.7%$39.69$39.69$39.13590,200
$39.87+0.21+0.5%$39.90$40.00$39.16499,000
$39.66+0.71+1.8%$39.74$40.50$38.87744,700
$38.95+0.45+1.2%$38.56$39.22$38.34375,521
$38.50+0.35+0.9%$38.13$38.93$37.48486,067
$38.15+0.08+0.2%$38.12$38.84$38.02380,000
$38.07-1.86-4.7%$39.61$40.02$37.93696,100
Ticker
NASDAQ:HRMY
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Harmony Biosciences Holdings, Inc. news

Harmony Biosciences Holdings, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
25 in the last 12 months · 175 in all · newest Nov 19, 2026 · oldest 2020
Calls
24 calls with a replay · 24 with a transcript · latest Nov 4, 2026
Decks
29 decks · latest Nov 4, 2026

Where Harmony Biosciences Holdings, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:HRMY · Home listing · This pageNASDAQUnited StatesUSD
BMV:HRMYBMVMexicoMXN
BIVA:HRMYBIVAMexicoMXN
Stuttgart:60HStuttgartGermanyEUR
BOATS:HRMYBOATSUnited StatesUSD

Valuation

P/E 10.7× against a median of 23.4×: 2nd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.29B USD
P/E
10.7×
EV/sales
1.3×
EV/EBITDA
5.4×
Price/book
1.8×
Gross margin
74.0%
Operating margin
22.2%
Net margin
18.1%
Debt to equity
0.1×
Beta vs S&P 500
0.57

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Harmony Biosciences Holdings, Inc. · NASDAQ:HRMYUS$1.91BUS$1.29B10.7×1.3×5.4×1.8×18.1%0.1×0.57
Henan Lingrui Pharmaceutial Co., Ltd. Class A · SSE:600285US$2.04BUS$1.89B16.4×3.2×n/a3.9×20.9%0.0×n/a
Novast Laboratories Ltd · SZSE:301569US$2.01BUS$1.80B43.0×11.9×n/a5.9×30.8%0.0×n/a
Aurinia Pharmaceuticals Inc · NASDAQ:AUPHUS$1.97BUS$1.92B6.3×6.0×n/a3.0×97.7%0.0×0.64
Alivus Life Sciences Ltd · NSE:ALIVUSUS$1.90BUS$1.80B26.3×6.2×18.1×4.9×24.9%0.0×n/a
Pfizer Limited · NSE:PFIZERUS$1.90BUS$1.24B20.5×4.3×11.8×4.0×32.4%0.0×n/a
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A · SSE:603707US$1.90BUS$1.52B29.8×2.5×n/a1.8×10.4%0.0×n/a
Shenzhen Kangtai Biological Products Co. Ltd. Class A · SZSE:300601US$1.80BUS$1.74B103×4.7×n/a1.2×4.8%0.2×n/a
Shilpa Medicare Limited · NSE:SHILPAMEDUS$1.79BUS$1.85B50.0×9.3×33.5×6.0×18.1%0.2×n/a
Dermapharm Holding SE · XETR:DMPUS$1.78BUS$2.88B12.4×2.2×6.9×2.9×11.1%2.0×n/a
Shenyang Xingqi Pharmaceutical Co., Ltd. Class A · SZSE:300573US$1.76BUS$1.69B14.6×4.0×n/a5.2×28.6%0.0×n/a
Median of the othersUS$1.90BUS$1.80B23.4×4.5×14.9×4.0×22.9%0.0×0.64

Forecasts

6 strong buy · 2 buy · 3 hold · 1 sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
48.08 USD · Analysts' mean
EPS, year to Dec 2026
4.76 · 2 analysts
Revenue, year to Dec 2026
1.03B · 12 analysts

Team and board

Officers

OfficerRole
Andreas WickiChief Executive Officer
Ron PhilipPresident and Chief Executive Officer
Glenn ReicinChief Financial Officer
Peter AnastasiouChief Operating Officer
Christian UlrichExecutive Vice President, General Counsel & Corporate Secretary
Adam ZaeskeExecutive Vice President and Chief Commercial Officer
Cate McCanlessSenior Vice President and Chief Corporate Affairs Officer
David UngerSenior Vice President, CMC and Technical Operations
Stephen MollichellaSenior Vice President and Controller, Interim Principal Financial Officer
Andrew SerafinChief Strategy Officer
Audrey MurphyChief Human Resources Officer
Jeffrey S. AroninHarmony Founder and Non-Executive Chairman
Kumar BudurChief Medical and Scientific Officer
Tricia GloverChief Compliance Officer

Board

DirectorRole
Jeffrey S. AroninHarmony Founder and Non-Executive Chairman

Events

Calls

CallWhenStatus
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2026 Earnings CallWed, Nov 04, 2026 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q2 2026 Earnings CallTue, Aug 04, 2026 · 5:00 PM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 2026 Earnings CallThu, May 07, 2026 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q4 2025 Earnings CallTue, Feb 24, 2026 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2025 Earnings CallTue, Nov 04, 2025 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q2 2025 Earnings CallTue, Aug 05, 2025 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 2025 Earnings CallTue, May 06, 2025 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q4 2024 Earnings CallTue, Feb 25, 2025 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2024 Earnings CallTue, Oct 29, 2024 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q2 2024 Earnings CallTue, Aug 06, 2024 · 8:30 AM ETReplay
All 24 calls
CallWhenStatus
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 2024 Earnings CallTue, Apr 30, 2024 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q4 2023 Earnings CallMon, Jan 08, 2024 · 8:00 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2023 Earnings CallTue, Oct 31, 2023 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q2 2023 Earnings CallTue, Aug 01, 2023 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 2023 Earnings CallTue, May 02, 2023 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q4 2022 Earnings CallTue, Feb 21, 2023 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2022 Earnings CallTue, Nov 01, 2022 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q2 2022 Earnings CallTue, Aug 02, 2022 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 2022 Earnings CallTue, May 03, 2022 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q4 2021 Earnings CallMon, Feb 28, 2022 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2021 Earnings CallTue, Nov 09, 2021 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q2 2021 Earnings CallTue, Aug 10, 2021 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 2021 Earnings CallTue, May 11, 2021 · 8:30 AM ETReplay
Harmony Biosciences Holdings (NASDAQ:HRMY) Q4 2020 Earnings CallThu, Mar 25, 2021 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open−7.0%
Q2 2026Aug 4, 2026 · Before open+8.9%
Q1 2026May 7, 2026 · Before open−4.2%
Q4 2025Feb 24, 2026+4.9%
Q3 2025Nov 4, 2025 · Before open+4.7%
Q2 2025Aug 5, 2025 · Before open−1.7%
Q1 2025Apr 28, 2025 · Before open−0.8%
Q4 2024Feb 25, 2025 · Before open+8.2%
Q3 2024Oct 29, 2024 · Before open+16.1%
Q2 2024Aug 6, 2024 · Before open+6.2%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 30, 2024 · Before open+5.7%
Q4 2023Feb 22, 2024 · Before open−4.7%
Q3 2023Oct 31, 2023 · Before open+19.4%
Q2 2023Aug 1, 2023 · Before open−3.9%
Q1 2023May 2, 2023 · Before open+2.4%
Q4 2022Feb 21, 2023 · Before open−11.1%
Q3 2022Nov 1, 2022 · Before open+14.0%
Q2 2022Aug 2, 2022 · Before open+12.6%
Q1 2022May 3, 2022 · Before open−17.6%
Q4 2021Feb 28, 2022 · Before open+5.3%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings22 slidesNov 4, 2026
Q2 2026 Earnings PresentationEarnings20 slidesAug 4, 2026
Q1 2026 Earnings PresentationEarnings26 slidesMay 7, 2026
Q1 2026 Earnings PresentationEarnings19 slidesMay 7, 2026
Q4 2025 Earnings PresentationEarnings18 slidesFeb 24, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)Conference26 slidesJan 12, 2026
Q3 2025 Earnings PresentationEarnings17 slidesNov 4, 2025
Q2 2025 Earnings PresentationEarnings16 slidesAug 5, 2025
Q1 2025 Earnings PresentationEarnings16 slidesMay 6, 2025
Q4 2024 Earnings PresentationEarnings18 slidesFeb 25, 2025
All 29 decks
DeckKindSlidesDate
43rd Annual JP Morgan Healthcare Conference (January 2025)Conference25 slidesJan 13, 2025
Q3 2024 Earnings PresentationEarnings22 slidesOct 29, 2024
Investor Day (October 2024)Investor day94 slidesOct 1, 2024
Q2 2024 Earnings PresentationEarnings14 slidesAug 6, 2024
Q1 2024 Earnings PresentationEarnings16 slidesApr 30, 2024
Q4 2023 Earnings PresentationEarnings14 slidesJan 8, 2024
Q3 2023 Earnings PresentationEarnings13 slidesOct 31, 2023
Q2 2023 Earnings PresentationEarnings13 slidesAug 1, 2023
Q1 2023 Earnings PresentationEarnings11 slidesMay 2, 2023
Q4 2022 Earnings PresentationEarnings11 slidesFeb 21, 2023
Q3 2022 Earnings PresentationEarnings14 slidesNov 1, 2022
Q2 2022 Earnings PresentationEarnings10 slidesAug 2, 2022
Q1 2022 Earnings PresentationEarnings12 slidesMay 3, 2022
Q4 2021 Earnings PresentationEarnings14 slidesFeb 28, 2022
Q3 2021 Earnings PresentationEarnings13 slidesNov 9, 2021
Q2 2021 Earnings PresentationEarnings15 slidesAug 11, 2021
Q1 2021 Earnings PresentationEarnings14 slidesMay 11, 2021
FY2020 Earnings PresentationEarnings16 slidesMar 25, 2021
Q3 2020 Earnings PresentationEarnings10 slidesNov 12, 2020

Open Decks

IPO

Priced at US$24.00 a share on Aug 18, 2020.

Price
US$24.00 a share
Shares offered
5,348,837 shares of common stock
Offering size
US$128.4 million
Underwriters' option
Up to 802,325 more shares
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Piper Sandler · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 14, 2020
Filed publiclyJul 27, 2020
Amended 3 timesNewest Aug 13, 2020
Shares registered with an exchangeAug 14, 2020
Declared effective by the SECAug 18, 2020
Final prospectus, with the priceAug 20, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Aug 20, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue868.5M714.7M582.0M437.9M305.4M159.7M6.00M0
Cost of revenue198.3M156.8M121.2M83.5M55.5M27.7M1.58M184.0K
Gross profit670.1M557.9M460.8M354.4M249.9M132.0M4.42M-184.0K
Research and development189.6M145.8M76.1M70.9M30.4M19.4M69.6M12.4M
Selling, general and administrative152.5M110.4M95.3M84.0M63.9M39.7M36.4M12.2M
Operating income208.5M190.8M192.0M120.2M87.5M17.0M-145.9M-41.4M
Depreciation and amortization25.3M267.0K514.0K419.0K416.0K394.0K395.0K184.0K
EBITDA233.8M191.1M192.5M120.6M87.9M17.4M-145.5M-41.3M
Interest expense14.6M17.5M23.8M18.8M24.2M28.6M7.36M0
Income before tax215.1M191.8M173.4M104.7M37.4M-36.9M-152.0M-39.9M
Income tax56.4M46.3M44.5M-76.8M2.83M14.9M6.07M1.54M
Net income158.7M145.5M128.9M181.5M34.6M-36.9M-152.0M-39.9M
Earnings per share, basic2.762.562.173.070.60-2.48-24.07-0.81
Earnings per share, diluted2.712.512.132.970.58-2.48-24.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents752.5M453.0M311.7M243.8M234.3M228.6M24.5M83.5M
Short-term investments22.8M14.2M41.8M79.3M0
Receivables96.8M83.0M74.1M54.7M34.8M22.2M4.25M0
Inventory5.36M7.20M5.36M4.30M4.43M3.82M1.09M0
Current assets907.0M579.3M451.1M400.3M284.4M262.9M31.5M86.7M
Property, plant and equipment1.26M371.0K573.0K820.0K938.0K1.33M1.58M
Total assets1.27B999.2M811.4M673.9M433.4M427.1M106.7M89.3M
Accounts payable17.7M13.7M17.7M3.79M1.00M2.56M6.36M1.46M
Current liabilities252.1M175.1M163.8M78.9M53.8M134.5M19.9M7.23M
Long-term debt143.7M163.0M178.6M189.6M190.0M194.3M97.9M
Total debt163.7M179.3M193.6M191.6M192.0M194.3M97.9M324.2M
Total liabilities401.4M340.0M344.5M271.0M246.9M329.9M118.3M7.75M
Shareholders' equity870.2M659.2M467.0M402.8M186.5M97.2M-422.9M81.5M
Shares outstanding57.7M57.1M56.8M59.6M58.8M56.9M7.79M49.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations348.2M219.8M219.4M144.5M98.6M-2.98M-75.4M-38.8M
Capital spending-310.0K-1.15M-312.0K-172.0K-298.0K-2.00K-149.0K-1.34M
Free cash flow347.9M218.7M219.1M144.3M98.3M-2.99M-75.6M-40.1M
Cash from investing-39.6M-67.5M-46.4M-141.8M-100.3M-2.00M-127.1M-1.34M
Cash from financing-9.05M-11.0M-105.6M6.84M7.42M209.2M143.8M21.6M
Dividends paid-5.05M-200.3M-143.8M
Share buybacks00-100.0M8.84M39.1M-167.0K-1.13M-3.20M
Change in cash299.5M141.3M67.4M9.47M5.68M204.2M-58.8M-18.5M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
8-K/A · Current report, amendedOct 30, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
8-K · Current reportOct 13, 2026Management or board changeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
144 · Notice of proposed saleSep 18, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 16, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 9, 2026Insider tradeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
3 · Initial statement of ownershipJul 22, 2026Insider tradeSEC
8-K · Current reportJul 16, 2026ResultsSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
8-K · Current reportMay 14, 2026Meeting outcomeSEC
144 · Notice of proposed saleMay 8, 2026Other filingsSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportApr 14, 2026Management or board changeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 6, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 3, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 3, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 3, 2026Meeting noticeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
144 · Notice of proposed saleJan 26, 2026Other filingsSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025ResultsSEC
8-K · Current reportOct 23, 2025ResultsSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
8-K · Current reportSep 24, 2025Current reportSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
8-K · Current reportJun 11, 2025Current reportSEC
144 · Notice of proposed saleJun 10, 2025Other filingsSEC
8-K · Current reportJun 5, 2025Current reportSEC
144 · Notice of proposed saleMay 19, 2025Other filingsSEC
144 · Notice of proposed saleMay 16, 2025Other filingsSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
8-K · Current reportMay 15, 2025Meeting outcomeSEC
144 · Notice of proposed saleMay 12, 2025Other filingsSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
144 · Notice of proposed saleMay 9, 2025Other filingsSEC
144 · Notice of proposed saleMay 8, 2025Other filingsSEC
144 · Notice of proposed saleMay 7, 2025Other filingsSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 29, 2025Big-stake noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2025Insider tradeSEC
UPLOAD · Letter from the SECApr 15, 2025Other filingsSEC
CORRESP · Letter to the SECApr 9, 2025Other filingsSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 4, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 4, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 4, 2025Meeting noticeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
8-K · Current reportApr 3, 2025Management or board changeSEC
144 · Notice of proposed saleApr 1, 2025Other filingsSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
UPLOAD · Letter from the SECMar 28, 2025Other filingsSEC
8-K · Current reportMar 24, 2025Management or board changeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
S-8 · Registration statement for employee plansFeb 25, 2025Offer documentSEC
S-3ASR · Registration statementFeb 25, 2025Offer documentSEC
10-K · Annual reportFeb 25, 2025Annual reportSEC
8-K · Current reportFeb 25, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2025Big-stake noticeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
144 · Notice of proposed saleJan 27, 2025Other filingsSEC
144 · Notice of proposed saleJan 27, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipJan 21, 2025Insider tradeSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
144 · Notice of proposed saleJan 13, 2025Other filingsSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
8-K · Current reportNov 1, 2024Current reportSEC
4 · Change in ownershipOct 31, 2024Insider tradeSEC
424B7 · ProspectusOct 31, 2024Offer documentSEC
424B7 · ProspectusOct 29, 2024Offer documentSEC
144 · Notice of proposed saleOct 29, 2024Other filingsSEC
10-Q · Quarterly reportOct 29, 2024Quarterly reportSEC
8-K · Current reportOct 29, 2024ResultsSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
144 · Notice of proposed saleOct 1, 2024Other filingsSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
8-K · Current reportOct 1, 2024Current reportSEC
144 · Notice of proposed saleSep 30, 2024Other filingsSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
8-K · Current reportAug 6, 2024ResultsSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportJul 1, 2024Management or board changeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
8-K · Current reportMay 29, 2024Meeting outcomeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
8-K · Current reportMay 3, 2024Management or board changeSEC
10-Q · Quarterly reportApr 30, 2024Quarterly reportSEC
8-K · Current reportApr 30, 2024ResultsSEC
ARS · Annual report to shareholdersApr 11, 2024Annual reportSEC
8-K · Current reportApr 11, 2024Material contractSEC
DEFA14A · Additional proxy materialApr 11, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 11, 2024Meeting noticeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
144 · Notice of proposed saleMar 15, 2024Other filingsSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
144 · Notice of proposed saleMar 8, 2024Other filingsSEC
10-K/A · Annual report, amendedFeb 28, 2024Annual reportSEC
S-8 · Registration statement for employee plansFeb 22, 2024Offer documentSEC
10-K · Annual reportFeb 22, 2024Annual reportSEC
8-K · Current reportFeb 22, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC

This page holds 200 of 461 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Harmony Biosciences Holdings, Inc.’s releases · as of Nov 2, 2026

Common shares
58,723,199
Fully diluted
58,723,199

Fully diluted

LineSharesAs of
Common shares58,723,199Nov 2, 2026

Share count over time

CountShares
Nov 2, 202658,723,199

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
BlackRock7.93M13.5%US$311M+827KNov 13, 2026
Vanguard5.62M9.6%US$221M+249KNov 13, 2026
Fidelity3.27M5.6%US$128M−305KNov 10, 2026
American Century3.11M5.3%US$122M+574KNov 20, 2026
Dimensional2.65M4.5%US$104M+256KNov 4, 2026
Lsv Asset Management2.21M3.8%US$86.6M+144KNov 6, 2026
State Street2.13M3.6%US$83.6M+271KNov 12, 2026
Geode Capital1.55M2.6%US$60.8M+107KNov 6, 2026
Armistice Capital, LLC1.44M2.4%US$56.4M−128KNov 16, 2026
Renaissance Technologies1.4M2.4%US$54.9M+202KNov 12, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Arrowstreet Capital, Limited Partnership1.27M2.2%US$49.7M−46,253Nov 13, 2026
Two Sigma1.14M1.9%US$44.7M+180KNov 16, 2026
Allspring Global Investments Holdings, LLC1.12M1.9%US$44.5M+951KNov 4, 2026
AQR Capital Management LLC1.02M1.7%US$40.2M+89,865Nov 16, 2026
Morgan Stanley786K1.3%US$30.9M+52,278Nov 13, 2026
UBS762K1.3%US$29.9M+74,896Nov 16, 2026
Invesco700K1.2%US$27.5M+171KNov 12, 2026
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main598K1.0%US$23.5M+46,625Nov 16, 2026
Goldman Sachs588K1.0%US$23.1M+185KNov 16, 2026
Nomura559K0.95%US$22M+53,417Nov 16, 2026
Schwab529K0.90%US$20.8M+105KNov 16, 2026
Northern Trust494K0.84%US$19.4M+22,402Nov 16, 2026
Boston Partners424K0.72%US$16.6M+393KNov 10, 2026
Victory Capital419K0.71%US$16.5M+20,068Nov 10, 2026
BNP Paribas413K0.70%US$16.2M−34,864Nov 12, 2026
Royce & Associates LP363K0.62%US$14.3M+649Nov 9, 2026
Principal362K0.62%US$14.2M+96,976Nov 2, 2026
Emerald Advisers, LLC351K0.60%US$13.8MNewNov 9, 2026
Tieton Capital Management, LLC305K0.52%US$12M−1,555Nov 10, 2026
Federated Hermes, Inc.301K0.51%US$11.8M+12,907Nov 12, 2026
Janus Henderson300K0.51%US$11.8MFirst reportNov 16, 2026
Franklin Templeton294K0.50%US$10.1M+101KNov 12, 2026
683 Capital Management, LLC293K0.50%US$11.5M−1,400Nov 16, 2026
BNY289K0.49%US$11.4M+16,521Nov 5, 2026
Capital Management Corp282K0.48%US$11.1M−3,635Oct 29, 2026
Bridgewater Associates, LP270K0.46%US$10.6M+21,694Nov 16, 2026
Bridge City Capital, LLC265K0.45%US$10.4M+55,539Oct 29, 2026
Los Angeles Capital Management LLC258K0.44%US$10.1M+200KNov 12, 2026
Universal- Beteiligungs- und Servicegesellschaft mbH253K0.43%US$9.92M−12,009Nov 10, 2026
Public Sector Pension Investment Board235K0.40%US$8.71M+34,102Nov 10, 2026
Opaleye Management Inc.230K0.39%US$9.03MNewNov 16, 2026
Pictet Asset Management Holding SA228K0.39%US$8.95M+30,834Nov 3, 2026
Emerald Mutual Fund Advisers Trust227K0.39%US$8.93MNewNov 9, 2026
Tetragon Partners GP Ltd227K0.39%US$8.9M+25,641Nov 16, 2026
CX Institutional218K0.37%US$8,554−41,614Oct 2, 2026
Man Group plc209K0.36%US$8.21M+66,751Nov 16, 2026
Handelsbanken Fonder AB206K0.35%US$8.1M+181KNov 9, 2026
Trexquant Investment LP197K0.34%US$7.75M+22,597Nov 16, 2026
Susquehanna170K0.29%US$6.69M−106KNov 16, 2026
Envestnet Asset Management Inc160K0.27%US$6.3M+107KNov 16, 2026

This page holds 50 of 348 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
iShares Core S&P Small-Cap ETF2.41M4.1%US$87.6M+23,357Jun 30, 2026
Avantis U.S. Small Cap Value ETF2.03M3.5%US$64.2M+335KMay 31, 2026
Vanguard Total Stock Market Index Fund1.56M2.7%US$56.7M−13,200Jun 30, 2026
iShares Russell 2000 ETF1.16M2.0%US$42.2M+90,579Jun 30, 2026
Vanguard Small-Cap Index Fund1.13M1.9%US$41.1M−6,400Jun 30, 2026
Fidelity Growth Company Fund1.01M1.7%US$31.8MNo changeMay 31, 2026
Vanguard Small-Cap Growth Index Fund654K1.1%US$23.8M+20,128Jun 30, 2026
Fidelity Small Cap Index Fund494K0.84%US$17.4M+61,380Jul 31, 2026
Vanguard Extended Market Index Fund462K0.79%US$16.8M+14,777Jun 30, 2026
Fidelity Enhanced Small Cap Core ETF457K0.78%US$16.7M+265KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
iShares Russell 2000 Growth ETF417K0.71%US$15.2M+60,782Jun 30, 2026
Invesco Pharmaceuticals ETF410K0.70%US$14.5M+63,670Jul 31, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF366K0.62%US$13.3M+2,970Jun 30, 2026
iShares S&P Small-Cap 600 Growth ETF361K0.61%US$13.1M+17,660Jun 30, 2026
Pacer US Small Cap Cash Cows 100 ETF341K0.58%US$12M+26,634Jul 31, 2026
U.S. Targeted Value Portfolio323K0.55%US$11.4M+22,800Jul 31, 2026
U.S. Small Cap Value Portfolio322K0.55%US$11.3M+151KJul 31, 2026
Dimensional U.S. Targeted Value ETF282K0.48%US$9.92M+39,966Jul 31, 2026
U.S. Small Cap Portfolio259K0.44%US$9.13MNo changeJul 31, 2026
Vanguard Tax-Managed Small-Cap Fund251K0.43%US$9.13MNo changeJun 30, 2026
Vanguard Russell 2000 Index Fund225K0.38%US$7.1M+8,024May 31, 2026
Janus Henderson Small/Mid Cap Growth Alpha ETF224K0.38%US$7.91MNewJul 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF221K0.38%US$8.06M+11,634Jun 30, 2026
Fidelity Extended Market Index Fund206K0.35%US$6.51M−2,281May 31, 2026
Dimensional U.S. Small Cap ETF191K0.32%US$6.72MNo changeJul 31, 2026
Schwab U.S. Small-Cap ETF191K0.32%US$6.02M−2,894May 31, 2026
U.S. Micro Cap Portfolio187K0.32%US$6.6MNo changeJul 31, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF184K0.31%US$6.71M−20,789Jun 30, 2026
MFS New Discovery Fund181K0.31%US$5.72MNo changeMay 31, 2026
BlackRock Advantage Small Cap Core Fund164K0.28%US$5.18M−2,048May 29, 2026
Select Pharmaceuticals Portfolio159K0.27%US$5.01MNo changeMay 31, 2026
Royce Small-Cap Fund158K0.27%US$5.74M+7,204Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF156K0.27%US$5.48M+9,170Jul 31, 2026
VictoryShares US Small Mid Cap Value Momentum ETF150K0.26%US$5.46M+10,804Jun 30, 2026
Bridge Builder Small/Mid Cap Value Fund147K0.25%US$5.34MNo changeJun 30, 2026
Fidelity Growth Company K6 Fund138K0.24%US$4.37M−1,806May 31, 2026
Allspring Opportunity Fund138K0.23%US$5.02M−2,485Jun 30, 2026
Vanguard S&P Small-Cap 600 Index Fund137K0.23%US$4.34M+965May 31, 2026
VictoryShares Small Cap Free Cash Flow ETF137K0.23%US$5M−12,260Jun 30, 2026
Applied Finance Explorer Fund130K0.22%US$4.59M+2,375Jul 31, 2026
Avantis U.S. Small Cap Value Fund130K0.22%US$4.11M+24,964May 31, 2026
Vanguard Health Care Index Fund130K0.22%US$4.09M+335May 31, 2026
LSV Small Cap Value Fund128K0.22%US$4.51MNo changeJul 31, 2026
Fidelity Series Growth Company Fund125K0.21%US$3.94M−19,000May 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund122K0.21%US$3.86M+7,484May 31, 2026
Strategic Advisers U.S. Total Stock Fund115K0.20%US$3.63M+5,175May 31, 2026
Dimensional US Small Cap Value ETF113K0.19%US$3.98M+23,489Jul 31, 2026
Schwab Small-Cap Index Fund110K0.19%US$3.88M+14,053Jul 31, 2026
Federated Hermes MDT Small Cap Core Fund106K0.18%US$3.73MNo changeJul 31, 2026
iShares U.S. Pharmaceuticals ETF104K0.18%US$3.78M−7,273Jun 30, 2026

This page holds 50 of 324 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Budur Kumar
Officer: CHIEF MEDICAL OFFICER
Sale35,852USD 43.05US$1.54MSep 18, 2026
Budur Kumar
Officer: CHIEF MEDICAL OFFICER
Sale800USD 43.00US$34,400Sep 17, 2026
Budur Kumar
Officer: CHIEF MEDICAL OFFICER
Sale1,800USD 43.01US$77,418Sep 16, 2026
Budur Kumar
Officer: CHIEF MEDICAL OFFICER
Sale4,500USD 42.25US$190KSep 8, 2026
Budur Kumar
Officer: CHIEF MEDICAL OFFICER
Sale1,000USD 42.79US$42,790Sep 8, 2026
Budur Kumar
Officer: CHIEF MEDICAL OFFICER
Sale22,954USD 43.10US$989KSep 8, 2026
Budur Kumar
Officer: CHIEF MEDICAL OFFICER
Sale5,500USD 41.98US$231KSep 4, 2026

Big stakes

HolderStakeSharesDate
BlackRock, Inc.12.60%7.36MSep 30, 2026
Marshman Fund Trust II10.60%6.05MDec 31, 2024
American Century Investment Management, Inc.5.40%3.11MSep 30, 2026
FMR LLC5.40%3.11MDec 31, 2025
Vanguard Portfolio Management LLC5.08%2.94MJun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gary Sender
Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); iBio, Inc. (Director · Since at least Oct 14, 2020); Schrodinger, Inc. (Board Member · Since at least Feb 5, 2020); Nabriva Therapeutics AG (Chief Financial Officer · Dec 30, 2016 – Feb 28, 2021 · Past); Synergy Pharmaceuticals Inc (EVP and CFO · Nov 16, 2015 – Nov 16, 2015 · Past)
Director · Since at least Aug 18, 2020
Geno Germano
Other companies: Entera Bio Ltd. (Chairman of the Board · Since at least Feb 4, 2026); Precision BioSciences, Inc. (Director · Since at least Mar 10, 2020); Sage Therapeutics Inc (Director · Since at least Jun 6, 2018); Bioverativ Inc (Director · Jan 31, 2018 – Mar 8, 2018 · Past); The Medicines Company (Director · Nov 9, 2017 – Jan 6, 2020 · Past)
Director · Since at least Apr 2, 2026
Troy Ignelzi
Other companies: Rapport Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 6, 2024); Contineum Therapeutics, Inc. (Chief Financial Officer, Rapport Therapeutics, Inc. · Since at least May 20, 2024); CinCor Pharma Inc (Director · Jan 6, 2022 – Feb 24, 2023 · Past); Karuna Therapeutics Inc (Chief Financial Officer · Jun 27, 2019 – Aug 22, 2023 · Past); Scpharmaceuticals Inc (Chief Financial Officer · Nov 16, 2017 – Jan 17, 2018 · Past)
Director · Since at least Apr 2, 2026
Mark Graf
Other companies: Marqeta, Inc. (Director · Since at least Jul 19, 2024); Signet Jewelers Limited (Director · Since at least Jul 1, 2017); Discover Financial Services (EVP & Chief Financial Officer · Apr 11, 2011 – Jul 25, 2019 · Past); BNC Bancorp (Director · Jun 15, 2010 – Sep 14, 2010 · Past)
Director · Since at least Nov 11, 2020
Antonio J. Gracias
Other companies: Space Exploration Technologies Corp (Board Member · Since at least Jun 11, 2026); SolarCity (Director · Dec 12, 2012 – Nov 21, 2016 · Past); Tesla, Inc. (Director · Jun 25, 2010 – Feb 8, 2021 · Past)
Director · Since at least Aug 18, 2020
Jack Nielsen
Other companies: Aligos Therapeutics, Inc. (Director · Jun 23, 2022 – Feb 27, 2024 · Past); ALX Oncology Holdings Inc. (Director · Jun 15, 2022 – Jun 20, 2023 · Past); Instil Bio, Inc. (Director · May 20, 2022 – Jun 14, 2023 · Past)
Director · Mar 30, 2022 – May 29, 2024 · Past
Sandip Kapadia
Other companies: Windward Bio Group AG (Experienced Life Sciences Board Member and Chief Financial Officer · Since at least Nov 16, 2026); Passage Bio, Inc. (Chief Financial Officer of Harmony Biosciences Holdings, Inc. · Since at least Feb 27, 2020); Intercept Pharmaceuticals Inc (CFO and Treasurer · Jul 1, 2016 – Jan 22, 2021 · Past)
CHIEF FINANCIAL OFFICER · Since at least Mar 29, 2021
Andreas Wicki
Other companies: Viela Bio Inc (Director · Oct 2, 2019 – Mar 13, 2021 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Mar 12, 2021 · Past)
Chief Executive Officer · Since at least Aug 18, 2020
Glenn Reicin
Other companies: Sigilon Therapeutics Inc (CHIEF FINANCIAL OFFICER · Dec 3, 2020 – Feb 11, 2021 · Past); Jasper Therapeutics, Inc. (Director · Nov 19, 2019 – Nov 19, 2019 · Past)
Chief Financial Officer · Since at least Apr 14, 2026
Susan L Drexler
Other companies: Rein Therapeutics, Inc. (See Remarks · Jun 15, 2022 – Jun 15, 2022 · Past); Kiora Pharmaceuticals, Inc. (Interim CFO · Apr 21, 2022 – Apr 21, 2022 · Past)
Chief Financial Officer · Aug 18, 2020 – Aug 18, 2020 · Past
All 29 people
PersonSeat
Jeffrey M. Dayno
Other companies: Egalet Corporation (Chief Medical Officer · Jul 31, 2014 – Jun 8, 2017 · Past)
PRESIDENT, CEO, Director · Since at least Aug 18, 2020
Jeffrey S. Aronin
Other companies: Discover Financial Services (Director · May 16, 2019 – May 11, 2023 · Past)
Harmony Founder and Non-Executive Chairman · Since at least Aug 18, 2020
John C. Jacobs
Other companies: Novavax, Inc. (President and Chief Executive Officer · Since at least Jan 23, 2023)
PRESIDENT, CEO, Director · Aug 18, 2020 – Aug 15, 2022 · Past
Linda Szyper
Other companies: Neos Therapeutics Inc (Director · Mar 19, 2021 – Mar 19, 2021 · Past)
Director · Since at least Nov 18, 2021
Ron M Philip
Other companies: Avalo Therapeutics, Inc. (Director · Since at least Jun 23, 2026)
Director · Since at least Apr 2, 2025
Ron Philip
Other companies: Avalo Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026)
President and Chief Executive Officer · Since at least Apr 3, 2025
Adam ZaeskeExecutive Vice President and Chief Commercial Officer · Since at least Mar 24, 2025
Andrew SerafinCHIEF STRATEGY OFFICER · Since at least Dec 2, 2022
Audrey MurphyChief Human Resources Officer · Since at least Nov 5, 2026
Cate McCanlessSenior Vice President and Chief Corporate Affairs Officer · Since at least Oct 20, 2026
Christian UlrichExecutive Vice President, General Counsel & Corporate Secretary · Since at least Nov 5, 2026
David UngerSenior Vice President, CMC and Technical Operations · Since at least Nov 5, 2026
Eric L MotleyDirector · Nov 11, 2020 – May 20, 2021 · Past
Jeffrey DierksCHIEF COMMERCIAL OFFICER · Aug 18, 2020 – Mar 3, 2025 · Past
Juan A SabaterDirector · Since at least Aug 18, 2020
Kumar BudurChief Medical and Scientific Officer · Since at least May 1, 2023
Peter AnastasiouChief Operating Officer · Since at least Nov 5, 2023
Stephen MollichellaSenior Vice President and Controller, Interim Principal Financial Officer · Since at least Jul 16, 2026
Tricia GloverChief Compliance Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Harmony Biosciences Holdings, Inc.